Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets
August 23, 2022 10:54 ET
|
Antisense Therapeutics Limited
World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated novel blood markers as potential diagnostic and therapeutic...
Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets
August 22, 2022 07:40 ET
|
Antisense Therapeutics Limited
World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated novel blood markers as potential diagnostic and therapeutic...
New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2
June 22, 2022 09:15 ET
|
Antisense Therapeutics Limited
LGMDR2, also referred to as dysferlinopathy, is a rare genetic muscle disease caused by mutations in the dysferlin gene (DYSF)Animal study conducted at MCRI in collaboration with Jain Foundation in...